Related Experiment Videos
Modulating fluorouracil with different drugs: the Padua experience
M V Fiorentino1, A Fornasiero, O Daniele
1Divisione di Oncologia Medica, Ospedale Civile di Padova, Italy.
Journal of Chemotherapy (Florence, Italy)
|February 1, 1990
Summary
Clinical findings suggest 5-fluorouracil combined with leucovorin, platinum, and alpha interferon shows promise. Intra-arterial and intraperitoneal administration may benefit specific patient groups, warranting further investigation.
Area of Science:
- Oncology
- Pharmacology
- Clinical Medicine
Background:
- 5-fluorouracil (5-FU) is a cornerstone chemotherapy agent.
- Modulation of 5-FU efficacy is crucial for improving treatment outcomes.
- Synergistic drug combinations are actively explored in cancer therapy.
Purpose of the Study:
- To evaluate the clinical efficacy of modulating 5-fluorouracil.
- To assess the benefits of adding leucovorin, platinum, and alpha interferon to 5-FU.
- To explore the impact of administration routes on treatment outcomes.
Main Methods:
- Retrospective analysis of clinical experiences from Padua, Italy.
- Evaluation of combination chemotherapy regimens including 5-FU, leucovorin, platinum, and alpha interferon.
- Assessment of intra-arterial and intraperitoneal drug delivery methods.
Main Results:
- Clinical experiences confirm that 5-fluorouracil (5-FU) can be effectively modulated.
- Addition of leucovorin, platinum, and alpha interferon demonstrated beneficial effects.
- Intra-arterial and intraperitoneal administration of these synergistic combinations showed promise in specific patient subsets.
Conclusions:
- Combination therapy with 5-FU, leucovorin, platinum, and alpha interferon offers a promising approach.
- Specific administration routes may enhance therapeutic benefits in selected patient populations.
- Further clinical studies are warranted to optimize these treatment strategies.